Nymox Pharmaceutical Corporation (Nasdaq: NYMX) announced that new Phase 3 prospective randomized clinical trial results have confirmed that patients who ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE